In the preclinical studies, BiKE has been effectively used to target CD19/CD22 on B cell non-Hodgkin's lymphoma, CD33 on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), EpCAM on various carcinomas, and CD133 on cancer stem cells [95]. This evidence concerns the gene CD22 and myelodysplastic syndrome.